Here's what we'll cover
Here's what we'll cover
If you're on Medicare and taking a GLP-1 medication like semaglutide or tirzepatide, you may have seen the headlines: some enrollees could soon pay just $50 a month for these drugs. That's a significant drop from the hundreds, or even thousands, many people currently pay out of pocket.
But as with most Medicare news, the details matter enormously. Not everyone qualifies, not every drug is included, and the timing depends on your specific plan. Here's what you actually need to know.
Why GLP-1 Costs on Medicare Are Changing
GLP-1 medications, short for glucagon-like peptide-1 receptor agonists, have become some of the most prescribed drugs in the United States. Drugs like Ozempic (semaglutide for type 2 diabetes) and Wegovy (semaglutide for weight loss) carry list prices that can exceed $900 to $1,300 per month without assistance.
For Medicare beneficiaries, who are often on fixed incomes, those prices have put these medications out of reach. Two major policy shifts are now changing that reality.
The Inflation Reduction Act's Role
The Inflation Reduction Act (IRA), signed into law in 2022, introduced several provisions aimed at lowering drug costs for Medicare enrollees. One of the most impactful is the $2,000 annual out-of-pocket cap on Part D drug spending, which phases in for 2025. Once you hit that cap, you pay nothing more for the rest of the year.
For high-cost medications like GLP-1 drugs, reaching that cap can happen within just a few months, which means many patients could pay $50 per month or less once they are through the initial coverage phases of their plan.
Medicare Drug Price Negotiation
The IRA also gave Medicare the authority to directly negotiate drug prices with manufacturers for the first time. While GLP-1 drugs are not yet in the first round of negotiated drugs, the broader cost-cap structure created by the law is what's driving the $50 figure being reported for this summer.
Who Actually Qualifies for the $50 Cap?
This is where many patients get confused, and understandably so. The $50 figure does not apply to every Medicare enrollee taking a GLP-1 medication. Here are the key conditions that determine your eligibility.
You Must Have Medicare Part D Coverage
The cost changes apply to Medicare Part D, which covers prescription drugs. If you have Original Medicare without a Part D plan, or if you get drug coverage through a Medicare Advantage plan, your situation may differ. Check your specific plan's formulary and out-of-pocket structure.
Your Diagnosis Matters
Medicare has historically covered GLP-1 drugs only for type 2 diabetes, not for obesity or weight management alone. Ozempic and Mounjaro (tirzepatide) have Part D coverage tied to a diabetes diagnosis. Wegovy, which is FDA-approved for weight management, has faced more limited Medicare coverage.
However, this is changing. In late 2023, the Centers for Medicare and Medicaid Services (CMS) finalized a rule expanding coverage for anti-obesity medications under Medicare Part D, with implementation underway. Whether your plan has adopted this coverage and which drugs are included depends on your specific insurer.
The Low-Income Subsidy Program (Extra Help)
If you qualify for Medicare's Extra Help program (also called the Low-Income Subsidy or LIS), you already receive reduced cost-sharing on Part D drugs. For 2025, full Extra Help beneficiaries pay no more than $4.50 for generics and $11.20 for brand-name drugs per month under standard rules. The broader $50 figure being discussed relates to the standard Part D out-of-pocket cap structure for all enrollees.
What the $50 Cap Looks Like in Practice
To understand how the $50 monthly figure works for most Part D enrollees, it helps to understand how Medicare Part D cost-sharing is structured in 2025.
The new Medicare Prescription Payment Plan (M3P), available starting January 2025, allows enrollees to spread their out-of-pocket drug costs evenly across monthly payments throughout the year. For someone taking a high-cost GLP-1 drug who would otherwise pay a large lump sum early in the year, this can translate to roughly $50 per month in smoothed payments, depending on your plan and drug costs.
This is the primary mechanism behind the "$50 this summer" framing you're seeing in news coverage.
Which GLP-1 Drugs Are Covered Under Medicare Part D?
Coverage varies by plan, but here is a general picture of where major GLP-1 medications stand with Medicare as of 2025.
If you're taking a GLP-1 drug primarily for weight loss and do not have a diabetes diagnosis, confirm with your plan whether Wegovy or Zepbound is on your formulary before assuming you're covered.
Steps to Take Before Summer to Maximize Your Savings
Knowing a cost reduction may be coming is useful. Knowing exactly what to do about it is better. Here are concrete steps to take now.
Step 1: Call Your Part D Plan Directly
Don't rely on general news coverage to know your specific situation. Call the member services number on the back of your Medicare card and ask three questions: Is my GLP-1 medication on your formulary? What tier is it on? Am I enrolled in the Medicare Prescription Payment Plan?
Step 2: Talk to Your Prescriber About Diagnosis Coding
If you have both type 2 diabetes and obesity, make sure your prescriber is coding your prescription appropriately. The diagnosis attached to your prescription affects whether it gets covered. Your doctor or their billing staff can confirm the right diagnostic code is being used.
Step 3: Apply for Extra Help If You Haven't Already
The Extra Help program can dramatically reduce what you pay for Part D drugs regardless of the new cap structure. You can apply through Social Security at ssa.gov. Eligibility is based on income and assets, and many people who qualify don't realize it.
Step 4: Enroll in the Medicare Prescription Payment Plan (M3P)
If you want to smooth your costs into monthly payments, you need to actively enroll in M3P through your Part D plan. It does not happen automatically. Contact your plan to ask how to sign up.
If You're Not on Medicare: What This Means for You
If you're under 65 or not yet on Medicare, you won't directly benefit from these changes. But the trajectory matters. As Medicare increasingly covers and pays for GLP-1 medications, it creates pricing pressure that can affect commercial insurance and employer-sponsored plans over time.
For now, if you're paying out of pocket or have limited commercial coverage, there are other pathways worth exploring. Manufacturer savings programs, compounding pharmacies (where available and legal), and telehealth providers often offer lower-cost access to semaglutide and tirzepatide. You can compare your options through Best Providers or look for available discounts through GLP-1 Coupons.
No waiting list. No insurance needed.
Frequently Asked Questions
Which Medicare enrollees will pay $50 for GLP-1 drugs?
Enrollees in Medicare Part D plans who are taking covered GLP-1 medications and who participate in the Medicare Prescription Payment Plan (M3P) may see their costs smoothed to roughly $50 per month. The exact amount depends on your plan, your drug, and your total annual out-of-pocket costs.
Is Wegovy covered by Medicare in 2025?
Coverage for Wegovy (semaglutide for weight loss) under Medicare Part D is expanding following a CMS rule change, but it is not guaranteed by all plans. Check your specific plan's formulary to confirm whether Wegovy is listed and under what conditions it is covered.
Does Medicare cover GLP-1 drugs for weight loss or only for diabetes?
Historically, Medicare covered GLP-1 drugs only for type 2 diabetes. A 2023 CMS rule began expanding coverage to include anti-obesity medications like Wegovy under Part D. However, coverage depends on your specific plan and whether it has implemented the new guidance.
What is the Medicare Prescription Payment Plan (M3P)?
M3P is a new optional program available starting in 2025 that lets Medicare Part D enrollees spread their annual out-of-pocket drug costs into equal monthly payments. For someone whose GLP-1 drug costs add up to $600 or more per year, this can mean paying roughly $50 per month instead of a large amount early in the year.
What is the Medicare Part D out-of-pocket cap for 2025?
In 2025, the maximum out-of-pocket spending for Medicare Part D drug costs is $2,000 per year. After you reach that threshold, you pay nothing more for covered drugs for the rest of the calendar year.
Can I get a GLP-1 drug covered by Medicare if I don't have diabetes?
It is increasingly possible, but it depends on your plan and your diagnosis. As of 2025, some Part D plans are covering Wegovy and Zepbound for obesity treatment. You should check your plan's formulary and talk to your doctor about whether your diagnosis qualifies under your specific coverage.